Surrozen, Inc.
- Jurisdiction
United States - ISIN
US86889P2083 (SRZN )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
1
/ 7
Profile
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. Read full profile
Stock price
Fundamentals
- Net revenue
€10.80M - Gross margin
96.4% - EBIT
-€22.20M - EBIT margin
-205.4% - Net income
-€14.29M - Net margin
-132.3%
Statement period: - (published )
Dividends
No dividend payouts
Earnings Calls
Latest earnings call: March 25, 2023
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Buy |